Shanghai Fosun Pharmaceutical (Group) Co., Ltd., operating under trade name Fosun Pharma, is a Chinese pharmaceutical company based in Shanghai, China.
On March 17, 2020, Fosun granted a $135 million investment to BioNTech in exchange for 1.58 million shares in BioNTech and the future development and marketing rights of the mRNA vaccine BNT162b2 in China.[1]
BioNTech in China alliance with Fosun over coronavirus vaccine candidate. (2020, March 16). Reuters. https://web.archive.org/web/20220720182255/https://www.reuters.com/article/biontech-fosunpharma-vaccine-collaborati/biontech-in-china-alliance-with-fosun-over-coronavirus-vaccine-candidate-idUSL8N2B90UW ↩︎